BioRestorative Therapies(BRTX) - 2022 Q4 - Annual Report

Securities registered pursuant to Section 12(g) of the Act: None (Title of Class) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ As of June 30, 2022, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was $8,495,444 based on the closing sale price as repor ...